Today was the day announced for a decision to be made.
The HSE’s Senior Management Team have approved the reimbursement of Skyclarys for patients with Friedreich’s Ataxia.
Today (25 August) was the day announced for a decision to be made.
HSE senior management met to discuss providing Skyclarys, as Biogen had made a new offer to the Health Service.
The outcome will result in strong engagement with Biogen over the coming years in respect of the treatment of Friedreich’s Ataxia.
The HSE's Drugs Group earlier this month recommended the drug not be reimbursed, over cost-effectiveness concerns.
Skyclarys is the first treatment for the condition, which is shown to slow the symptoms by up to 50pc.
Kfm news had previously spoken to Niamh Ní Hoireabhaird about her experiences with FA, and Craig Coady, a father of two teenage boys have suffered with the disease, one of whom sadly passed away as a result.
The progressive neuro muscular disease causes nerve damage, muscle weakness and mobility loss.
Approximately 200 people are affected by the disease in Ireland.
Teenager Dies On E-Scooter Following Collision On Clare-Limerick Border
SSE Airtricity Customers To See Gas And Electricity Price Hikes From October
Russian Ambassador Says Irish Government "Cannot Be Treated As A Friendly One"
Two People Arrested In Connection With Shooting Near Dublin Shopping Centre
New Report Shows House Prices Are 17% Overvalued
Boy Dies After Train Collides With Car In Mayo
E-Scooter Ban For Under 18s Could Be In Place By October
Teenager Charged After Alleged Wrong-Way Driving Incident In Cork City
